The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Subscribe To Our Newsletter & Stay Updated
